Yang T, Yu H, Han D, Xie Z. Combined mesenchymal and neural stem cell therapy enhances neurological recovery in cerebral infarction. World J Stem Cells 2025; 17(9): 110663 [DOI: 10.4252/wjsc.v17.i9.110663]
Corresponding Author of This Article
Hui Yu, Department of Emergency, Affiliated Hospital of Jiangnan University, No. 1000 Hefeng Road, Binhu District, Wuxi 214000, Jiangsu Province, China. yuhuiyh56@163.com
Research Domain of This Article
Emergency Medicine
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Sep 26, 2025; 17(9): 110663 Published online Sep 26, 2025. doi: 10.4252/wjsc.v17.i9.110663
Combined mesenchymal and neural stem cell therapy enhances neurological recovery in cerebral infarction
Ting Yang, Hui Yu, Dong Han, Zheng Xie
Ting Yang, Hui Yu, Dong Han, Zheng Xie, Department of Emergency, Affiliated Hospital of Jiangnan University, Wuxi 214000, Jiangsu Province, China
Author contributions: Yang T conducted the majority of experiments and wrote the manuscript; Yu H designed the study and served as a scientific advisor and guarantor; Han D corrected the manuscript; Xie Z was involved in applying the analytical tools; Han D and Xie Z participated in the collection of human material.
Institutional review board statement: This study was approved by the Institutional Ethics Committee Affiliated Hospital of Jiangnan University (Wuxi, China).
Clinical trial registration statement: The study design was approved by the Institutional Ethics Committee and adhered to the principles of the Declaration of Helsinki. However, the trial was not prospectively registered in the Chinese Clinical Trial Registry for the following reasons. Initially categorized as an exploratory clinical application of novel cell therapy rather than a formal interventional clinical trial, thus not mandating registration.
Informed consent statement: All patients provided informed consent to participate.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: All data collection and analyses were ethically reviewed, with informed consent obtained from all participants. The raw data are available for verification upon request. Technical appendix, statistical code, and dataset are available from the corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Yu, Department of Emergency, Affiliated Hospital of Jiangnan University, No. 1000 Hefeng Road, Binhu District, Wuxi 214000, Jiangsu Province, China. yuhuiyh56@163.com
Received: June 13, 2025 Revised: July 22, 2025 Accepted: September 4, 2025 Published online: September 26, 2025 Processing time: 102 Days and 19.9 Hours
Core Tip
Core Tip: Combination therapy with neural stem cell (NSC) and mesenchymal stem cell (MSC) promotes neurological recovery in patients with acute cerebral infarction (ACI) by modulating vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression, thereby enhancing cerebral perfusion, daily living capacity, and neurological function scores. This study validated the efficacy and safety of NSC/MSC stem cell combination therapy, and systematically elucidated the mechanistic roles of VEGF and bFGF in the NSC-MSC-mediated treatment of ACI. These findings further demonstrate the central regulatory roles of VEGF and bFGF in angiogenesis and neural repair, thereby advancing the application of precision medicine in ACI treatment, and providing a robust theoretical foundation and future directions for clinical translation.
